The dexmethylphenidate drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The dexmethylphenidate drug is used to control the symptoms of attention deficit hyperactivity disorder (AAHD) in adults and children. The drug belongs to a group of medicines called the central nervous system (CNS). The rise in the prevalence of ADHD across the globe is anticipated to drive the growth of the global dexmethylphenidate drug market during the forecast period. For instance, according to the data published by National Center for Biotechnology Information (NCBI) in 2021, the prevalence of ADHD accounted for 139.4 million people out of which 2.5% registered for persistent adult ADHD and 6.7% for symptomatic ADHD. Moreover, 366.3 million adults were affected by ADHD in 2020 globally.
The rise in the prevalence of Narcolepsy in the US is one of the major factors in driving the growth of the global dexmethylphenidate drug market. Narcolepsy is a chronic neurological disorder that affects the brain’s ability to control sleep-wake cycles. For instance, according to the data published by American Sleep Association (ASA) in 2021, approximately 50-70 million US adults have a sleep disorder out of which 37.9% reported unintentionally falling asleep during the day. Moreover, the incidence of narcolepsy accounted for 50 per 100,000 people in the US .further 10,000 mortalities occur in the US, due to sleep deprivation annually.
Looking towards the demand for dexmethylphenidate drugs key market players are adopting various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in March 2021, KemPharma, Inc., has received the USFDA approval for Azstarys, for the treatment of attention deficit hyperactivity disorder (ADHD) patients age 6 years and older. Moreover, Corium Inc. (Gurnet Point Capital) will market the Azstarys as per the agreement and collaboration between KemPharma Inc. and an affiliate of GPC. Moreover, in January 2021, Glenmark Pharmaceuticals received the USFDA approval for Amphetamine sulfate tablets USP 5mg, 10mg for the treatment of attention deficit hyperactivity disorder and narcolepsy in adults.
In October 2020, the US FDA has approved Pitolisant for the treatment of cataplexy in adults with narcolepsy. Further, in June 2020, Esai Inc. launched the orexin receptor antagonist Dayvigo, for the treatment of adults with insomnia associated with difficulties with sleep onset and sleep maintenance in the US. Moreover, Dayvigo was approved by the USFDA based on the findings with the lemborexant clinical development program in nearly 2000 adult patients with insomnia.
For instance, in March 2019, Jazz Pharmaceuticals received the US Food and Drug Administration (FDA) approval for Sunosi, to improve the wakefulness with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). Further, according to an assessment by the Patient Global Impression of change scale (PGlc), in 12-week clinical studies, approximately 68.0-74.0% of people taking Sunosi at the 75mg dose reported an improvement in their clinical condition. Thus, such product launches and approvals are anticipated to drive the growth of the global dexmethylphenidate drug market during the forecast period.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Global Dexmethylphenidate Drug Marketat https://orionmarketreports.com/request-sample/?id=92684&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Age Group
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape– Sun Pharmaceutical Industries Ltd, Novartis International AG, and Teva Pharmaceutical Industries Ltd among others.
A full report is available at: https://orionmarketreports.com/global-dexmethylphenidate-drug/92684/
Global Dexmethylphenidate Drug Market Report by Segment
By Type
- Tablets
- Capsules
By Age Group
- Children (6-17 years )
- Adults
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
